Omniab Inc (OABI) Stock Price, Quote & News

Company Profile

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 250 7800

Website: www.omniab.com

Address:

5980 Horton Street, Suite 600, EmeryVille, United States

WallStreetVice May. 13 at 9:53 PM

$OABI $CLFD $MBAI $GSIT }{57

0 · Reply

PlannedTrading101 May. 13 at 6:18 PM

$OABI On the money. Still lots of room to go!

0 · Reply

WeighProtein May. 12 at 9:17 PM

$OABI Might look into shorting this 🙃

1 · Reply

PlannedTrading101 May. 12 at 5:13 PM

$OABI Price Targets:

0 · Reply

PlannedTrading101 May. 12 at 4:57 PM

$OABI Print baby, print! 2.50+

0 · Reply

MarketBeat May. 8 at 8:03 PM

OmniAb Q1 Earnings Call Highlights $OABI #OmniAb #instantalerts #NASDAQ:OABI https://www.marketbeat.com/instant-alerts/omniab-q1-earnings-c

0 · Reply

PlannedTrading101 May. 8 at 2:29 PM

$OABI Just starting! 🔥

0 · Reply

StocktwitsEarnings May. 7 at 8:23 PM

$OABI Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.06 up 64.71% YoY • Reported revenue of $14.43M up 247.30% YoY • OmniAb raised 2026 revenue guidance to $28M-$33M from $25M-$30M. Costs and operating expenses are now expected between $83M-$88M, up from $80M-$85M. Cash and cash equivalents guidance was also raised to $33M-$38M.

0 · Reply

PlannedTrading101 May. 7 at 5:35 PM

$OABI At Support area. Holding for 2.50+. Long here.

0 · Reply

SuperGreenToday May. 6 at 3:20 PM

$OABI Share Price: $1.39 Contract Selected: Oct 16, 2026 $2.5 Calls Buy Zone: $0.08 – $0.09 Target Zone: $0.14 – $0.17 Potential Upside: 68% ROI Time to Expiration: 162 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

OmniAb reports Q1 EPS (6c), consensus (10c)

2026-05-07T22:45:12.000Z - 6 days ago

OmniAb raises FY26 revenue view to $28M-$33M, consensus $28.0M

May 7, 2026, 4:30 PM EDT - 6 days ago

OmniAb Earnings Call Transcript: Q1 2026

May 7, 2026, 4:05 PM EDT - 6 days ago

OmniAb Reports First Quarter 2026 Financial Results and Business Highlights

Apr 24, 2026, 8:00 AM EDT - 19 days ago

OmniAb to Participate in Three Upcoming Investor Conferences

Apr 21, 2026, 8:00 AM EDT - 22 days ago

OmniAb to Report First Quarter 2026 Financial Results on May 7

Mar 4, 2026, 4:30 PM EST - 2 months ago

OmniAb Earnings Call Transcript: Q4 2025

2026-03-04T21:21:33.000Z - 2 months ago

OmniAb reports Q4 EPS (11c), consensus (9c)

2026-03-04T21:21:03.000Z - 2 months ago

OmniAb sees FY26 revenue $25M-$30M, consensus $32M

Mar 4, 2026, 4:05 PM EST - 2 months ago

OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Feb 24, 2026, 8:00 AM EST - 2 months ago

OmniAb to Participate at the Leerink Partners Global Healthcare Conference

Feb 19, 2026, 8:00 AM EST - 2 months ago

OmniAb to Report Fourth Quarter 2025 Financial Results on March 4

Dec 15, 2025, 5:00 PM EST - 5 months ago

OmniAb Transcript: Investor Update

Dec 15, 2025, 4:05 PM EST - 5 months ago

Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies

2025-12-15T14:55:08.000Z - 5 months ago

OmniAb management to meet virtually with Craig-Hallum

Dec 4, 2025, 4:05 PM EST - 5 months ago

OmniAb to Hold OmniUltra Virtual Investor Event on December 15

2025-11-17T22:30:10.000Z - 6 months ago

OmniAb signs agreement for antibody discovery with new incubated company

BANX

Nov 17, 2025, 5:23 PM EST - 6 months ago

OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors

2025-11-05T14:22:39.000Z - 6 months ago

OmniAb price target lowered to $7 from $10 at Craig-Hallum

Nov 4, 2025, 4:30 PM EST - 6 months ago

OmniAb Earnings Call Transcript: Q3 2025

2025-11-04T21:20:48.000Z - 6 months ago

OmniAb reports Q3 EPS (14c), consensus (14c)

2025-11-04T21:20:37.000Z - 6 months ago

OmniAb sees FY25 revenue $18M-$22M, consensus $21.7M

Nov 4, 2025, 4:05 PM EST - 6 months ago

OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights

Oct 16, 2025, 8:00 AM EDT - 7 months ago

OmniAb to Participate in Three Investor Conferences in November

Oct 14, 2025, 8:00 AM EDT - 7 months ago

OmniAb to Report Third Quarter 2025 Financial Results on November 4

2025-09-12T20:05:15.000Z - 8 months ago

OmniAb files to sell 21.25M shares of common stock for holders

Sep 2, 2025, 8:00 AM EDT - 9 months ago

OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-25T11:10:11.000Z - 9 months ago

OmniAb to sell 21.254M shares at $1.40 in private placement

Aug 25, 2025, 7:00 AM EDT - 9 months ago

OmniAb Announces $30 Million Private Placement

Aug 6, 2025, 4:30 PM EDT - 10 months ago

OmniAb Earnings Call Transcript: Q2 2025

2025-08-06T20:28:37.000Z - 10 months ago

OmniAb reports Q2 EPS (15c), consensus (15c)

Aug 6, 2025, 4:05 PM EDT - 10 months ago

OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights

Jul 16, 2025, 8:00 AM EDT - 10 months ago

OmniAb to Report Second Quarter 2025 Financial Results on August 6

May 13, 2025, 4:05 PM EDT - 1 year ago

OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit

May 8, 2025, 4:30 PM EDT - 1 year ago

OmniAb Earnings Call Transcript: Q1 2025

2025-05-08T20:29:10.000Z - 1 year ago

OmniAb reports Q1 EPS (17c), consensus (17c)

2025-05-08T20:28:12.000Z - 1 year ago

OmniAb backs FY25 revenue view $20M-$25M, consensus $23.03M

May 8, 2025, 4:06 PM EDT - 1 year ago

OmniAb Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:05 PM EDT - 1 year ago

OmniAb Introduces the xPloration® Partner Access Program

May 5, 2025, 1:00 AM EDT - 1 year ago

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

May 1, 2025, 8:00 AM EDT - 1 year ago

OmniAb to Participate in Five Upcoming Investor Conferences

Apr 21, 2025, 8:00 AM EDT - 1 year ago

OmniAb Announces Two New Appointments to its Board of Directors

2025-04-17T11:50:09.000Z - 1 year ago

OmniAb management to meet with Truist

2025-03-27T12:16:16.000Z - 1 year ago

OmniAb price target lowered to $4 from $7 at RBC Capital

2025-03-23T00:31:36.000Z - 1 year ago

Analysts Maintain Strong Buy Rating for OmniAb Stock (OABI) Despite Price Decline

2025-03-21T13:46:09.000Z - 1 year ago

OmniAb price target lowered to $4 from $8 at TD Cowen

2025-03-20T11:22:35.000Z - 1 year ago

OmniAb price target lowered to $6 from $8 at Benchmark

Mar 18, 2025, 4:30 PM EDT - 1 year ago

OmniAb Earnings Call Transcript: Q4 2024

2025-03-18T20:16:47.000Z - 1 year ago

OmniAb sees FY25 revenue $20M-$25M, consensus $45.98M

Mar 18, 2025, 4:05 PM EDT - 1 year ago

OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Feb 24, 2025, 8:00 AM EST - 1 year ago

OmniAb to Report Fourth Quarter 2024 Financial Results on March 18

Feb 3, 2025, 4:57 PM EST - 1 year ago

OmniAb to Participate in Two Investor Conferences in March

Jan 31, 2025, 11:09 AM EST - 1 year ago

Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm

Dec 16, 2024, 4:15 PM EST - 1 year ago

OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference

Nov 12, 2024, 4:30 PM EST - 1 year ago

OmniAb Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights

Oct 30, 2024, 8:00 AM EDT - 1 year ago

OmniAb to Participate in Two Investor Conferences in November

Oct 22, 2024, 8:00 AM EDT - 1 year ago

OmniAb to Report Third Quarter 2024 Financial Results on November 12

Aug 26, 2024, 8:00 AM EDT - 1 year ago

OmniAb to Participate in Two Investor Conferences in September

Aug 8, 2024, 4:30 PM EDT - 1 year ago

OmniAb Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:05 PM EDT - 1 year ago

OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights

Jul 25, 2024, 8:00 AM EDT - 1 year ago

OmniAb to Report Second Quarter 2024 Financial Results on August 8

Jun 5, 2024, 8:00 AM EDT - 2 years ago

OmniAb Transcript: Jefferies Global Healthcare Conference

Jun 3, 2024, 4:05 PM EDT - 2 years ago

OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology

May 20, 2024, 8:05 AM EDT - 2 years ago

OmniAb to Participate in the Jefferies Global Healthcare Conference

May 15, 2024, 4:05 PM EDT - 2 years ago

OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit

May 15, 2024, 11:30 AM EDT - 2 years ago

OmniAb Transcript: RBC Capital Markets 2024 Global Healthcare Conference

May 9, 2024, 4:30 PM EDT - 2 years ago

OmniAb Earnings Call Transcript: Q1 2024

May 9, 2024, 4:05 PM EDT - 2 years ago

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights

May 1, 2024, 8:00 AM EDT - 2 years ago

OmniAb to Participate in Five Investor Conferences in May

Apr 22, 2024, 8:00 AM EDT - 2 years ago

OmniAb to Report First Quarter 2024 Financial Results on May 9

Apr 15, 2024, 8:31 AM EDT - 2 years ago

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

CNTN

Mar 20, 2024, 4:30 PM EDT - 2 years ago

OmniAb Earnings Call Transcript: Q4 2023

Mar 20, 2024, 4:05 PM EDT - 2 years ago

OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Feb 26, 2024, 8:00 AM EST - 2 years ago

OmniAb to Report Fourth Quarter 2023 Financial Results on March 20

Dec 14, 2023, 4:30 PM EST - 2 years ago

OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference

Nov 9, 2023, 5:55 PM EST - 2 years ago

OmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today's Research & Technology Virtual Event

Nov 9, 2023, 11:00 AM EST - 2 years ago

OmniAb Earnings Call Transcript: Q3 2023

Nov 9, 2023, 8:00 AM EST - 2 years ago

OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 1, 2023, 9:00 AM EDT - 2 years ago

OmniAb Appoints Steve Love to its Board of Directors

Oct 31, 2023, 4:28 PM EDT - 2 years ago

OmniAb Announces Agenda for its Research & Technology Virtual Event

Oct 12, 2023, 8:00 AM EDT - 2 years ago

OmniAb to Hold Research & Technology Virtual Event on November 9

Aug 10, 2023, 4:30 PM EDT - 2 years ago

OmniAb Earnings Call Transcript: Q2 2023

Aug 10, 2023, 4:05 PM EDT - 2 years ago

OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 7, 2023, 4:05 PM EDT - 3 years ago

OmniAb Announces the Passing of Director Sunil Patel

WallStreetVice May. 13 at 9:53 PM

$OABI $CLFD $MBAI $GSIT }{57

0 · Reply

PlannedTrading101 May. 13 at 6:18 PM

$OABI On the money. Still lots of room to go!

0 · Reply

WeighProtein May. 12 at 9:17 PM

$OABI Might look into shorting this 🙃

1 · Reply

PlannedTrading101 May. 12 at 5:13 PM

$OABI Price Targets:

0 · Reply

PlannedTrading101 May. 12 at 4:57 PM

$OABI Print baby, print! 2.50+

0 · Reply

MarketBeat May. 8 at 8:03 PM

OmniAb Q1 Earnings Call Highlights $OABI #OmniAb #instantalerts #NASDAQ:OABI https://www.marketbeat.com/instant-alerts/omniab-q1-earnings-c

0 · Reply

PlannedTrading101 May. 8 at 2:29 PM

$OABI Just starting! 🔥

0 · Reply

StocktwitsEarnings May. 7 at 8:23 PM

0 · Reply

PlannedTrading101 May. 7 at 5:35 PM

$OABI At Support area. Holding for 2.50+. Long here.

0 · Reply

SuperGreenToday May. 6 at 3:20 PM

0 · Reply

a36er May. 3 at 3:16 PM

$OABI Alright board. It's going to be a pretty interesting week coming up for this little security. Here's my dumb take behind OmniAB right now- The thinking behind AI being an adversary to animal testing is the wrong approach (in the short to intermediate timeframe). Smaller transgenic animal testing companies such as OmniAB are now potential acquisition targets (or at least partner candidates) for these AI companies so that the work can be proofed and checked. The drug discovery industry moves at a snail's pace regarding regulations and I see OmniAB's assets as synergies to a company developing these new discovery platforms. This might be Gotham's view as well who knows. Volume has steadily been increasing for months, and the market cap tells me this will be a deSPAC that actually makes it down the road. Only hold up I have for really big immanent moves is the warrant price action has gone to the graveyard. The real boat anchor here is the potential for more equity offerings.

0 · Reply

PlannedTrading101 May. 1 at 5:22 PM

$OABI Been accumulating. Looking to add more down here in this range. Anything below 1.40 is a steal IMO.

1 · Reply

bearsoil Apr. 29 at 10:33 PM

$OABI All in all with three presentations set up next month I doubt there would be any imminent major disappointing news on the horizon. Averging down

0 · Reply

a36er Apr. 29 at 5:37 PM

$OABI Alright stocktwits board, who’s buying? We all get this is a Ligand spinoff and even worse it was done via SPAC but this is a real company with real assets. The powers that be must really want this next round of equity cheap.

0 · Reply

bearsoil Apr. 29 at 12:26 PM

$OABI Positives: Conviction from :CEO bought one million worth of stock at 1.85. Former LGND CEO owns almost 3 million shares. For the most part large holders have been holding. Negatives: Soon will have to raise money and will be at this low evaluation. Managements forecasts are always very near term leaving question marks about when profitable can be reached. Management never gives much color about how business is tending. Final Analysis: OABI has uniquely positioned itself with a science in a trending field. It’s a competitive field. Biotechs of OABIs size are out of favor now. Might be bumpy however there certainly could be a nice percent gain from this depressed price. Would be great to see some insider buys at this point. Also more than usual information from upcoming earnings call would be helpful. During the price drop of the past 6 months most major holders have been holding. Trading volume has been low.

1 · Reply

a36er Apr. 28 at 4:58 PM

$OABI Well, Back to the private offering price institutions had....usually not a good sign when retail get's the same opportunity. PLACE YOUR BETS!

0 · Reply

bearsoil Apr. 14 at 5:22 PM

$OABI It appears that there has been institutional trading these last 2 days. There has been a big increase in trading volume with no price change. This might be attributed to accumulation or distribution between institutions prearranged with market makers. Resetting of positions before an announcement (earnings etc. ) is common . Often this type of trading proceeds a price move up after a stock has been in a long term down trend.

2 · Reply

a36er Mar. 31 at 4:07 PM

$OABI Orders are filling too easy. I think we're heading lower.

0 · Reply

bearsoil Mar. 24 at 6:21 PM

$OABI Trading under 1.70 today makes for a good entry point. The introduction of the Omni Ultra Platform in late 2025 is a big thing. The Oeptide therapeutic space is huge. Investors are overlooking OABI because they are seeing low revenue along with the losses. Revenue growth will likely turn OABI profitable in 2028 or 9 Should have a good revenue base in the next year or two after that. By then the stock will be much higher than today.

0 · Reply

OfficialStocktwitsUser Mar. 24 at 5:30 PM

$OABI RSI: 42.35, MACD: -0.0117 Vol: 0.09, MA20: 1.83, MA50: 1.82 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

PlannedTrading101 Mar. 10 at 5:19 PM

$OABI 2.50 - 3.00+ will come.

0 · Reply

a36er Mar. 5 at 5:23 AM

$OABI xPloration is probably going to have more legs to it than thought. Not a bad call.

0 · Reply

Market Cap	241.79M
Revenue (ttm)	18.67M
Net Income (ttm)	-64.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-346.97%
Debt to Equity Ratio	0.00

Volume	1,249,000
Avg Vol	575,310
Day's Range	N/A - N/A
Shares Out	144.78M
Stochastic %K	93%
Beta	0.07
Analysts	Strong Sell
Price Target	$7.33